1. Home
  2. PRVA vs DYN Comparison

PRVA vs DYN Comparison

Compare PRVA & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Privia Health Group Inc.

PRVA

Privia Health Group Inc.

HOLD

Current Price

$24.75

Market Cap

2.7B

Sector

Technology

ML Signal

HOLD

DYN

Dyne Therapeutics Inc.

HOLD

Current Price

$17.45

Market Cap

3.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRVA
DYN
Founded
2007
1984
Country
United States
United States
Employees
N/A
N/A
Industry
Retail: Computer Software & Peripheral Equipment
Medicinal Chemicals and Botanical Products
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.7B
3.0B
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
PRVA
DYN
Price
$24.75
$17.45
Analyst Decision
Buy
Strong Buy
Analyst Count
12
14
Target Price
$31.17
$37.00
AVG Volume (30 Days)
718.7K
1.7M
Earning Date
05-07-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
63.64
N/A
EPS
0.18
N/A
Revenue
$2,122,842,000.00
N/A
Revenue This Year
$18.19
N/A
Revenue Next Year
$10.72
N/A
P/E Ratio
$138.06
N/A
Revenue Growth
22.26
N/A
52 Week Low
$18.78
$8.25
52 Week High
$26.51
$25.00

Technical Indicators

Market Signals
Indicator
PRVA
DYN
Relative Strength Index (RSI) 66.49 41.97
Support Level $22.63 $16.47
Resistance Level $25.23 $19.65
Average True Range (ATR) 0.73 0.98
MACD 0.13 -0.30
Stochastic Oscillator 81.98 5.45

Price Performance

Historical Comparison
PRVA
DYN

About PRVA Privia Health Group Inc.

Privia Health Group Inc is one of the physician enablement companies in the United States with a presence in around 24 states and the District of Columbia. The group builds scaled provider networks with primary-care centric medical groups, risk-bearing entities, a physician-led governance structure, and the Privia Platform comprising an extensive suite of technology and service solutions. It collaborates with medical groups, health plans, and health systems to optimize approximately 1,300+ physician practices, improve the patient experience for over 5.8+ million patients, and reward around 5,300+ physicians and practitioners for delivering high-value care.

About DYN Dyne Therapeutics Inc.

Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease being treated, a linker, and an antigen-binding fragment that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.

Share on Social Networks: